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Abstract
Background: Hepatitis C virus (HCV) could induce chronic liver diseases and hepatocellular carcinoma in human.
The use of primary human hepatocyte as a viral host is restrained with the scarcity of tissue supply. A culture model
restricted to HCV genotype 2a (JFH-1) has been established using Huh7-derived hepatocyte. Other genotypes including
the wild-type virus could not propagate in Huh7, Huh7.5 and Huh7.5.1 cells.
Methods: Functional hepatocyte-like cells (HLCs) were developed from normal human iPS cells as a host for HCV
infection. Mature HLCs were identified for selective hepatocyte markers, CYP450s, HCV associated receptors and HCV
essential host factors. HLCs were either transfected with JFH-1 HCV RNA or infected with HCV particles derived from
patient serum. The enhancing effect of α-tocopherol and the inhibitory effects of INF-α, ribavirin and sofosbuvir to HCV
infection were studied. The HCV viral load and HCV RNA were assayed for the infection efficiency.
Results: The fully-developed HLCs expressed phase I, II, and III drug-metabolizing enzymes, HCV associated receptors
(claudin-1, occludin, CD81, ApoE, ApoB, LDL-R) and HCV essential host factors (miR-122 and SEC14L2) comparable to
the primary human hepatocyte. SEC14L2, an α-tocopherol transfer protein, was expressed in HLCs, but not in Huh7 cell,
had been implicated in effective HCVser infection. The HLCs permitted not only the replication of HCV RNA, but also
the production of HCV particles (HCVcc) released to the culture media. HLCs drove higher propagation of HCVcc
derived from JFH-1 than did the classical host Huh7 cells. HLCs infected with either JFH-1 or wild-type HCV expressed
HCV core antigen, NS5A, NS5B, NS3 and HCV negative-stand RNA. HLCs allowed entire HCV life cycle derived from
either JFH-1, HCVcc or wild-type HCV (genotype 1a, 1b, 3a, 3b, 6f and 6n). Further increasing the HCVser infection in
HLCs was achieved by incubating cell with α-tocopherol. The supernatant from infected HLCs could infect both naïve
HLC and Huh7 cell. Treating infected HLC with INF-α and ribavirin decreased HCV RNA in both the cellular fraction and
the culture medium. The HLCs reacted to HCVcc or wild-type HCV infection by upregulating TNF-α, IL-28B and IL-29.
Conclusions: This robust cell culture model for serum-derived HCV using HLCs as host cells provides a remarkable
system for investigating HCV life cycle, HCV-associated hepatocellular carcinoma development and the screening for
new anti HCV drugs.
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Background
Human primary hepatocytes should have served as ideal
host cells for liver-targeting pathogens, e.g., malarial
parasite, hepatitis B, hepatitis C and dengue viruses. The
shortcoming in the procurement of these cells and their
limited life span have limited the study of host-pathogen
relationships and their sequential developments, e.g.,
xenobiotic screening, and biotransformation. A cellular
substitute that closely mimics primary hepatocyte but
circumvents these shortcoming would greatly extend
our understanding of host-pathogen interactions and the
corresponding treatment strategies.
Hepatitis C virus (HCV) [1] is a single positive-
stranded RNA virus in the genus of Hepacivirus and
Flaviviridae family [2]. Chronic HCV infection led to
cirrhosis and hepatocellular carcinoma [3]. The self-
renewal capability of liver cell was disrupted that eventu-
ally required liver transplantation or bio-artificial liver
device [4]. Liver transplantation were faced with serious
and faster HCV reinfection to the graft [5, 6]. An alter-
native for liver transplant was the hepatocyte transplant
that might alleviate the demand of donor organs [7].
Direct-acting antivirals (DAA) targeting HCV enzymes
was hampered with eventual drug resistance [8–10]. The
development of suitable culture models for HCV is
critical for designing efficacious anti-HCV strategies.
The studies on HCV life cycle relied heavily on human
hepatocellular carcinoma cells (Huh7 and their deriva-
tives) [11]. HCV genotype 2a (JFH-1), but not others,
could be generated from Huh7 derived cells [12, 13].
The use of hepatocellular carcinoma as cellular host
could not completely mimic primary human hepatocyte.
The cancer cells actively entered cellular division while
the primary hepatocytes were mostly in quiescent stage
[14]. Most hepatoma cell lines usually lack various func-
tional enzymes such as CYP450s and other phase I, II
and III drug metabolizing enzymes that make them not
suitable for the assessment of anti-HCV drug interaction
and metabolism [15, 16]. Huh7.5.1 was derived from
Huh7.5 [17], which in turn was originated from Huh7
[18]. These cells carried a mutation in the retinoic-
inducible gene I (RIG-I) [19]. RIG-I played a central role
in viral genome recognition and host immune response.
Primary human hepatocytes have been indorsed by sev-
eral groups as the major host cells for HCV [20–22].
However, the handling primary human hepatocytes faced
several limitations: 1) The mature hepatocytes could not
be readily proliferated in culture condition; 2) The donor
supply was limited; and 3) The batch to batch variation
was substantial [23].
Human induced pluripotent stem (iPS) cells could be
generated from somatic cell through exogenous expres-
sion of Oct4, Sox2, KLF4 and c-MYC [24, 25]. Human
iPS cells actively entered cellular division and could be
differentiated into hepatocyte-like cells (HLCs) [26] and
others. The use of HLCs derived from either iPS or
embryonic stem cells as cellular hosts for HCV were re-
cently reported [27–30]. These differentiated cells dis-
played essential liver functions and achieved nearly
mature hepatocytes [31], including α-fetoprotein, albu-
min, phase I and phase II drug metabolizing enzymes.
HLCs also expressed known HCV host receptors in-
volved in HCV entry (Claudin-1, Occludin, SR-BI,
CD81) and supported complete life cycle of HCV geno-
type 2a up to 21 days [30]. Nevertheless, the maturity,
homogeneity and long-term stability of these HLCs have
not been revealed. The HLCs not only carried less
CYP450 expression than that of primary hepatocytes,
but retained several fetal hepatocyte markers.
In this studies, human iPS cells generated from hMSCs
using polycistronic OSKM reprograming factors [32]
were differentiated into HLCs. The CYP expressions
were readily inducible upon the exposure to the proto-
typic inducers in a similar fashion to the primary hepa-
tocytes. Since the HCV cell receptors and cell host
factors were highly expressed, these HLCs were
promptly taken as HCV hosts. The infected cells were
studied for viral life cycle after the transfection/infection
with HCVcc and HCVser. HLCs could sustain the repli-
cation of not only JFH-1 HCV but several wild-type
HCV’s from patients’ sera. High HCV titers were de-
tected in culture medium for at least 6 months. The
released HCV virions could infect naïve HLCs and were
susceptible to the treatment with interferon, ribavirin or
sofosbuvir.
Methods
Generation of human induced pluripotent stem cell
(hiPSC) from hMSC
The mononuclear cells were separated from bone marrow
using IsoPrep (Robbins Scientific, Canada) density gradi-
ent centrifugation. Isolated cells were seeded at 2 × 106
cells on T-75 cell culture flask in Minimum Essential
Medium (MEM) α (Gibco Invitrogen, NY), 10 % FBS
(HyClone, GE Healthcare Life Sciences, Singapore), 100
units/mL penicillin, 100 μg/mL streptomycin at 37 °C in
5 % CO2. Lentiviral particles were produced by co-
transfection of packaging psPAX2 packaging plasmid,
pMD2.G vesicular stomatitis virus G envelope, and the
polycistronic plasmid encoding human OCT4, SOX2,
KLF4, c-MYC and dTomato [32] using X-tremeGENE HP
DNA Transfection Reagent (Roche Diagnostics, USA).
hMSCs were transduced with concentrated lentivirus
(MOI = 0.5). Production of dTomato was observed 48 h
post-transduction. The transduced cells were seeded on
MEF in hES medium to promote reprogramming process
and colony formation. Reprogrammed colonies were iden-
tified with StainAlive TRA-1-60 Antibody (Stemgent,
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MA). Positive colonies were manually picked and pas-
saged until stable iPS cells established.
Maintaining and characterization of hiPSC
Human iPS cells were maintained in a feeder free condi-
tion on Geltrex-coated dish in E8 medium at 37 °C in
5 % CO2. The E8 medium consisted of DMEM/F12 sup-
plemented with 64 mg/L L-ascorbic acid-2-phosphate,
14 μg/L sodium selenite, 100 μg/L FGF2, 19.4 mg/L in-
sulin, 543 mg/L NaHCO3, 10.7 mg/L transferrin and
2 μg/L TGF-β1. The medium was changed daily. Human
iPS cell colonies were split at a ratio of 1:8 every 5 - 7 d
and passaged onto a new Geltrex-coated dish. The iPSC
colonies after the tenth passage were characterized for
pluripotent markers, e.g., alkaline phosphatase, OCT4,
SOX2, NANOG, TRA-1-60, TRA-1-81, and SSEA4 using
alkaline phosphatase ES characterization kit (MERCK
Millipore, USA), fluorescent antibody staining and quan-
titative RT-PCR analysis.
Teratoma formation
Approximately 2 × 106 iPS cells were subcutaneously
injected into nude mice (BALB/cMlac-nu). The tumor-
like tissue was collected within 8–12 weeks after injection.
The tissue was fixed in 10 % formalin and underwent
histological processes. The tissue sections were stained
with hematoxylin and eosin and examined under a light
microscope for the presence of the specialized cells de-
rived from three germ layers. All experiments performed
on laboratory animals were reviewed and approved by the
Animal Care and Use Committee, Institute of Molecular
Biosciences, Mahidol University.
Differentiation of hiPSC to homogeneous hepatocyte-like
cell
The characterized iPS cells were taken for hepatic induc-
tion. They were seeded on Geltrex-coated 6 well plate in
E8 medium until 80 % confluence and differentiated
using a modified hepatic lineage development protocol
[31]. Briefly, the cultured cells were maintained in endo-
derm differentiation medium DMEM/F12 : IMDM (1:1)
(Gibco Invitrogen, NY), 100 ng/mL activin A (Pepro-
Tech, US), 10 ng/mL bFGF, 10 ng/mL BMP-4, 1 μM
LY294002 and 3 μM CHIR99021 for 24 h. Cells were
maintained in endoderm commitment medium DMEM/
F12 : IMDM (1:1), 100 ng/mL activin A, 100 ng/mL
bFGF, 10 ng/mL BMP-4 and 1 μM LY294002 for 24 h.
The endoderm-like cells were further maintained in
anterior definitive endoderm differentiation medium
RPMI/B27 with 50 ng/mL activin A for 3 d with a daily
medium replacement. The differentiated cells were
maintained in hepatic lineage specification medium
RPMI/B27, 20 ng/mL BMP-4 and 10 ng/mL FGF10 for 4
d with daily medium replacement. The differentiated
cells were cultured in hepatocyte basal medium (HBM,
Lonza, UK), 30 ng/mL oncostatin M and 50 ng/mL HGF
for 10 d with medium replacement every 2 d. For func-
tional hepatocyte induction, the cells were cultured in
Williams' Media E (Invitrogen, MD, 1 % DMSO for 3 d.
Periodic acid-Schiff staining of glycogen
HLCs and hMSCs were cultured on 35-mm dish for 3d.
The cells were fixed in 5 % formaldehyde, 95 % ethanol
for 1 min, rinsed for 1 min under running tap water,
immersed in periodic acid solution for 5 min, rinsed thrice
with dH2O, immersed in Schiff ’s reagent for 15 min, and
rinsed with running tap water for 5–10 min. Samples were
counterstained with Mayer’s hematoxylin for 1 min, rinsed
with water, and assessed under light microscope.
Hepatocyte-specific markers and cytochrome P450
expressions
The total RNA was extracted from iPS cells, HLCs, or
HepaRG (HPRGC10, Life Technologies) by illustra RNAs-
pin Mini RNA Isolation Kit (GE Healthcare, Asia Pacific)
following the manufacturer instruction. The total RNA
was immediately used for reverse transcription to con-
struct cDNA using the ImProm-II reverse transcription
system (Promega, WI) following the manufacturer in-
struction. The hepatocyte markers and cytochrome P450
markers included albumin, α-fetoprotein, cytokeratin18,
G-6-PD, HNF-4α, tyrosine aminotransferase and major 7
CYPs isozymes. All gene specific primers (Additional file
1) were designed using vector NTI version 11.5 (Invitro-
gen, MD). They were amplified using KAPA SYBR® FAST
qPCR Kits (Kapa Biosystems). Each sample was measured
in triplicate. PCR amplicons were confirmed using size
and melting curve analysis. Expression levels were calcu-
lated using the ΔΔCt method and normalized to the en-
dogenous GAPDH. ΔΔCt was transformed into fold
change using the formula: fold change = 2- ΔΔCt.
Immunofluorescent staining
HLCs on 24-well plate were fixed with 4 % paraformal-
dehyde for 20 min at room temperature. The fixed cells
were washed thrice with PBS, blocked and permeabilized
with 0.2 % Triton X-100, 3 % BSA and 2 % normal goat
serum for 1 h. Primary antibodies against pluripotent
markers were TRA-1-60 (1:250, SC21705, Santa Cruz Bio-
technology), SSEA4 (1:250, ab16287, Abcam), NANOG
(1:250, SC33759, Santa Cruz Biotechnology), OCT4
(1:250, SC5279, Santa Cruz Biotechnology). Primary anti-
bodies against HCV cell receptors were claudin-1 (1:100,
ab15098), occluding (1:100, ab31721), CD81 (1:100,
ab79559), SR-BI (1:200, ab106572) and hepatitis C core
antigen (1:200, ab2740) ordered from Abcam. Primary
antibodies against non-structural proteins of HCV were
NS3 (1:200, SC69938), NS5A (1:200, SC52417) and NS5B
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(1:200, SC58146) ordered from Santa Cruz Biotechnology.
The cells were incubated with the primary antibody for
overnight h at 4 °C in moist chamber. After washing thrice,
samples were incubated with the secondary antibody;
Alexa fluor 488 conjugated goat anti-mouse IgG (1:1000,
A11001) or Alexa fluor 488 conjugated goat anti-rabbit
IgG (1: 1000, A11003s) or Alexa fluor 488 conjugated
rabbit anti-goat IgG (1: 1000, A1178) (Life Technologies)
for 1 h at 37 °C. Fibroblasts or untreated hMSCs served as
negative controls. After washing thrice, the cells were
counterstained with DAPI and mounted with anti-fade
mounting medium in coverslip and examined under a
fluorescent microscope and photographed.
The induction of major CYP450 isozymes in HepaRG and
HLCs using the enzyme inducer cocktail
The expression of CYP450 levels of hepatocyte-like cells
responded to enzyme inducers was evaluated after incu-
bate with cocktail of classical drugs [33]. HepaRG and
hepatocyte-like cell derived from iPS cells were seeded
on 6 well-plates for 3 d. These cells were maintained in
Williams’ Media E, 10 % FBS before exposure to the in-
ducers. Both of hepatocyte cells were incubated for 72 h
with the cocktail agent: 20 μM rifampicin, 50 μM omep-
razole, 1 mM phenobarbital and 88 μM ethanol. The
treated cells were washed with 2–3 mL PBS, detached
using 0.025 % trypsin-EDTA, and neutralized with 10 %
FBS in DMEM/F12. The cell pellets from hepatocyte-
like cell and HepaRG were stored at -80 °C until analysis
for CYP450 gene expression.
The detection of CYP450 activities
CYP1A1, CYP2B6, CYP2C9 and CYP3A4 enzyme activ-
ities were evaluated directly in all cultured cells (HepaRG,
HLCs and primary human hepatocytes) attaching to the
collagen type IV-coated 6-cm dish at a density of 106 cell.
All cultured cells were treated with a cocktail of 20 μM ri-
fampicin, 50 μM omeprazole, 1 mM phenobarbital and
88 μM ethanol. All treated cells were incubated for 72 h
with daily medium change. CYP450 activities were
assessed based on luciferase activity using the P450-glo
1A1, 2B6, 2C9 and 3A4 assays (V8751, V8321, V8791,
V9001; Promega, WI). After 3-d incubation period, cells
were incubated with Williams’ Media E supplemented
with 100 μM Luciferin-CEE, Luciferin-2B6, Luciferin-H
for 3–4 h or 3 μM Luciferin-IPA for 30–60 min. An
aliquot (50 μL) of the medium was transferred to 96-well
opaque white luminometer plate (Nunc, Denmark)
and luciferin detection reagent was added to each
well. After sitting at room temperature for 20 min,
luminescence was measured with a SpectraMax M5
spectrofluorometer.
The detection of cellular hepatitis C receptors on HLCs
HCV infection requires several types of cellular receptors
to permit viral entry [34]. Cellular receptors essential for
HCV infection such as Claudin-1, Occludin, SR-BI, CD81
were detected using quantitative RT-PCR and immuno-
fluorescent technique. Mature HLCs were seeded on 24-
well plate and maintained until 80 % confluence in
Williams’ Media E, 10 % FBS. Cells were fixed and stained
with fluorescent-conjugated antibodies raised against
Claudin-1, Occludin, SR-BI or CD81.
Production of HCV from JFH-1 (HCVcc)
Cell culture based hepatitis C virus (HCVcc genotype
2a) was prepared from JFH-1 system [35]. The JFH-1
plasmid was propagated in E Coli and extracted using
NucleoBond Xtra Midi plasmid (MN, Germany). The
plasmids were purified and linearized by a restriction
enzyme XbaI, and used as a template for JFH-1 RNA
synthesis. The full length HCV RNA was synthesized by
TranscriptAid T7 High Yield Transcription Kit (Thermo
Fisher Scientific, MA) following the manufacturer’s in-
struction. HCVcc was produced by transient transfection
of JFH-1 RNA into Huh7 cell using either lipofectamine
3000 (Invitrogen, MA) or electroporation (Gene Pulser
Xcell Electroporation Systems, Bio-Rad, CA). HCV in
Huh7 supernatant was passed through 0.45 μm syringe
filter, concentrated by sucrose gradient ultracentrifuga-
tion and stored at −80 °C for future use.
The infection of HCVser and HCVcc to HLCs
HCV-positive sera were collected from patients with
chronic HCV infection at Ramathibodi Hospital, Mahidol
University. The collection of leftover blood specimen was
approved by the Ethics Committee on Research Involving
Human Subjects (2556/250). All subjects are adults and
provided written informed consent. Serum from individ-
ual patient with HCV load > 106 IU/mL was selected to
infect HLCs. These sera carried HCV genotypes 1a, 1b, 3a,
3b, 6f and 6n that were prevalent in Thailand. For HCVser
and HCVcc infection, HLCs and Huh7 cells were seeded
on 6-well plate in Williams' Media E, 10 % FBS until 80 %
confluence. Some host cells were pretreated with 1 μM or
5 μM α-tocopherol for 24 h prior to HCVser infection.
For HCVser infection, 50 μL of infected serum in 2 mL of
medium was added to host cells. For HCVcc infection,
concentrated JFH-1 HCV load at 107 IU/mL in 2 mL of
medium was added to host cells. After 24 h incubation,
the infected cells were washed 6–10 times with 0.1 %
BSA in PBS and reconstituted with 2 mL complete
growth medium.
The long-term maintenance of HCV infection
For long-term HCV infection assay, HLCs and Huh7
were infected with HCVcc or HCVser. After 24 h
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incubation, the culture medium was renewed with 10 %
FBS, DMEM/F12. The HCV-containing supernatant was
collected ever 4–6 days and HCV RNA was detected
using RT-PCR. During long-term cultivation process,
HLCs and Huh7 cell were maintained in complete
medium with 1 % concentrated lipids (Life Technologies,
USA) and 1 μM (α-tocopherol). The HCV production
was confirmed using the Abbott real-time HCV assay
(Abbott Diagnostics, Illinois, USA).
The detection of negative and positive stands of HCV
RNA
HCV RNA in the supernatants was extracted with
NucleoSpin RNA Virus isolation kit (MN, USA); while the
intracellular RNA was extracted with illustra RNAspin Mini
RNA Isolation Kit (GE Healthcare, Asia Pacific). The stand
specific primers were designed using Vector NTI version
11.5 (Invitrogen, USA). The primers for positive strand are:
5′-CCCTGTGAGGAACTACTGTCTTCACGCA-3′ and
5′-CTCGCAAGCACCCTATCAGG-CAGTAC-3′. The
primers for the negative strand are: 5′-GATGTACCCCAT
GAGGTCGG-3′ and 5′-GCGCGACAAG-GAAGACTT
CG-3′ [36]. The viral RNA and total RNA from infected
host cells were converted to cDNA with the ImProm-II
reverse transcription system (Promega, WI). For HCV (-)
stand, one microgram of isolated RNA was incubated with
12.5 μM HCV ‘reverse’ primers in a total volume of 5 μL at
70 °C for 5 min and chilled on ice-water immediately for at
least 5 min. The reverse transcription mix (15 μL of 5× re-
action buffer, 25 mM MgCl2, 2 mM dNTP Mix, 40 U/μL
RNasin ribonuclease inhibitor, and 200 U/μL Improm-II™
RT) was added to the RNA-primer mix to make a total
volume of 20 μL. The mixture was incubated at 25 °C for
5 min, and 42 °C for further 1 h. The RT reaction was ter-
minated by heating at 70 °C for 15 min followed by chilling
on ice. The HCV cDNA was amplified by KAPA SYBR®
FAST qPCR Kits (Kapa Biosystems, UK) and 2.5 μM
HCV ‘forward’ primer at 95 °C for 30 s, 66 °C for 45 s
and 70 °C for 90 s. Hepatitis C virus (+) stand was
quantified by real-time RT-PCR using the m2000sp and
m2000rt instruments and RealTime HCV kit (Abbott
Diagnostics, Illinois, USA).
Statistical analysis
All results of experiments were performed in tripli-
cated. Data were expressed as means ± SD. Data from
quantitative real-time RT-PCR were evaluated for stat-
istical significance using either students’ t test or
ANOVA for difference followed by post-hoc tests
(Tukey’s HSD) between the treatments and their re-
spective controls. * and ** represented statistically dif-
ferent data with p < 0.05 and p < 0.01 respectively.
Results
Reprogramming human bone marrow mesenchymal stem
cell to iPS cells
hMSC isolated from aspirated bone marrow exhibited
spindle-shaped morphology at 90–95 % confluence
(Fig. 1a). After infecting hMSCs with polycistronic OSKM-
dTomato lentivirus particles for 48 h, the transduced
hMSCs expressing OCT4, SOX2, KLF4 and C-MYC were
determined by positive dTomato (Fig. 1b and c). The
dTomato-positive cells were detached and seeded on mito-
mycin c-treated MEF feeder at 2 × 105 cells/10-cm dish.
Cell morphology of dTomato positive population trans-
formed from spindle-shape to epithelial morphology
around day 5 post-transduction (Fig. 1d). These cell popu-
lations divided and formed a small cluster of dTomato
after 2-3 d (Fig. 1e). The transduced colonies expanded
and transformed to a tightly packed colony with a high
nucleocytoplasmic ratio (Fig. 1f). Upon reaching full repro-
gramming, dTomato expression was silenced and repro-
gramming colonies were negative for dTomato on day 13
as monitored under a fluorescence microscope (Fig. 1g).
The transduced cells reached iPS as determined by their
positive pluripotent surface marker TRA-1-60 using a live
staining technique (Fig. 1h and i). The TRA-1-60 positive
colonies were selected and picked into a new MEF-seeded
plates for expansion and characterizations.
Identification of pluripotent markers in reprogramming
cells and iPS cell characterizations
TRA-1-60-positive colonies were passaged and main-
tained on MEF in ES medium until reprogramming cells
achieved a typical human ESC morphology. The cell
morphology consisted of a sharp border, flat, dense col-
ony, high nucleocytoplasmic ratio and prominent nucleoli
(Fig. 1h). The karyotype analysis confirmed no chromo-
somal alteration (Fig. 1j). The establishment of human iPS
cell was confirmed using alkaline phosphatase (AP) activ-
ity, immunofluorescent staining of pluripotent markers
and the expression of pluripotent genes (Fig. 1k). The re-
programming cells were maintained in E8 medium with
feeder-free condition on Geltrex-coated dishes (Invitro-
gen, USA) prior to the analysis (Fig. 1l). The colony of re-
programming cells highly expressed essential pluripotent
marker proteins, OCT4 and SOX2, required for maintain-
ing pluripotent status. The expressions of OCT4 and
SOX2 targeted proteins such as the self-renewal transcrip-
tion factor NANOG, transmembrane proteins TRA-1-60
and TRA-1-81, and a cell surface glycoprotein SSEA4
were also expressed in the reprogramming cells. Human
fibroblasts were used as negative controls for non-iPS cells
(Fig. 2a). Exogenous OCT4 and SOX2 produced from the
lentivirus were active at the early stage of cell reprogram-
ming. To confirm the maintenance of endogenous OCT4
and SOX2 expression, specific OCT4 and SOX2 primers
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were designed to detect only the mRNA from endogenous
source. The RT-PCR analysis confirmed the transduced
cells carried endogenous OCT4 and SOX2 (Fig. 2b). Other
pluripotent markers such as REX1, NANOG, GDF3,
DNM3TB and UFT1 were expressed in the transduced
cells and compared with those in human ES cell (BG01V)
and non-transduced hMSCs (Fig. 2b). GAPDH and NTC
served as positive and negative controls for PCR products.
Spontaneous differentiation and teratoma formation
To determine whether these newly established iPS cells
could differentiate into all three germ layers, the iPS cells
Fig. 1 The generation of human iPS cell from hMSC. hMSC isolated from healthy donor at 2nd passage had spindle-shape (a). hMSCs after transduced
with polycistronic OSKM-dTomato lentivirus for 48 h was observed under a light microscope (b) and visualized for the staining of dTomato under a
fluorescent microscope (c). Five days after the transduction, the transduced cells transformed to epithelial-like morphology forming clusters of
dTomato-positive cells on day 7 (d, e). The cell colonies expanded and became tightly packed (f). The exogenous expression of OSKM were
silenced and confirmed by negative dTomato (g). After achieving fully reprogramming, the stable colonies were observed (h) and expressed
pluripotent surface marker TRA-1-60 (i). The iPS colonies were analyzed for karyotype (j). The colony was positive for alkaline phosphatase activity (k)
and maintained in feeder-free condition (l)
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were evaluated for ex vivo and in vivo differentiation. For
spontaneous ex vivo differentiation, iPS cells were main-
tained in suspension culture with embryoid bodies forma-
tion within a week. After 2 weeks, embryoid bodies were
seeded on gelatin-coated culture plates to allow cell adhe-
sion and migration. The adherent cells displayed various
morphologies (Fig. 3a). Immunofluorescent staining re-
vealed differentiated cell positive for βIII-tubulin (ectoderm
marker), vimentin (mesoderm marker) and α-fetoprotein
(AFP, endoderm marker) (Fig. 3a). These indicated the dif-
ferentiation to several lineages. For teratoma formation,
one million iPS cells were resuspended in DMEM 10 %
FBS and injected subcutaneously into nude mice. Four
weeks after injection, teratoma was formed at the injection
site. Histological examinations revealed that the teratoma
contained several tissues (Fig. 3b), e.g., neural rosette (ecto-
derm) (Fig. 3b, left panel), mesoderm derived smooth
muscle, adipose tissue, cartilage (mesoderm) (Fig. 3b, mid-
dle) and endoderm-derived gut-like epithelial (endoderm)
(Fig. 3b, right). Taken together, iPS cells derived from
hMSCs not only support the spontaneous ex vivo differen-
tiation but they can form teratoma in vivo.
The hepatocyte-like cell derived from iPS cell expressed
hepatic phenotypes
Human iPS cells were cultured in feeder free condition
until reaching 70 % confluence before hepatic induction
(Fig. 4a). During hepatic differentiation, iPS cells were
monitored daily for morphological changes. Initially,
iPS cells were differentiated into definitive endoderm
(DE) cells (Fig. 4b) that shared the same precursor with
all endodermal organs (pancreas, liver, lung, thyroid
and gut) [37]. The differentiated cell transformed into
round-shaped morphology (Fig. 4b) with positive stain-
ing for SOX17, an endoderm differentiation marker
(Fig. 4c). The second stage, definitive endoderm cells
were developed to anterior definitive endoderm (ADE)
with cell morphology underwent epithelial to mesen-
chymal transition (EMT) [38]. Cells displayed the
mesenchymal-like morphology (Fig. 4d). At the third
stage of differentiation, ADE cells became hepatic pro-
genitors (Fig. 4e). The differentiated cell at this stage
was confirmed with the expression of alpha-fetoprotein
(AFP) (Fig. 4f ), a characteristic of hepatoblast [31]. At
maturation, hepatoblasts developed into functional
hepatocyte-like cells (HLCs). HLCs shared both fetal
and adult hepatocyte markers, e.g., albumin and min-
imal level of alpha-fetoprotein (Fig. 4g). The expression
of HNF4-α, found only at the end of maturation, re-
vealed that the cells fully developed into mature hepa-
tocytes (Fig. 4h). After 4-week differentiation, human
iPS cell developed into a near homogenous population
with more than 95 % pure hepatocyte-like cell. HLCs
exhibited typical hepatocyte morphology, e.g., a polygonal
Fig. 2 Identifications of pluripotent markers in human iPS cells derived from hMSCs. Newly established iPS cells were stained with monoclonal
antibodies against pluripotent protein markers, e.g., Nanog, Oct-4, Sox2, SSEA4, Tra-1-60 and Tra-1-81. The iPS cells were counter stained with DAPI
and visualized under a fluorescent microscope. Human fibroblast served as negative controls (a). To elucidate endogenous expressions of pluripotent
markers in human iPS cells, specific primers were designed to detect the endogenous expression of Oct4, Sox2, Klf4, c-MYC, Nanog, REX1,
GDF3, DNM3TB and UTF1 (b). The iPS cells (lane 1) expressed all pluripotent genes similarly to those of hES (BG01V: lane 2). Normal hMSC
expressed only Klf4 and C-MYC (lane 3). PCR products from mouse embryonic fibroblast sample (lane 4) and NTC (lane 5) served as negative controls
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shape, a dark cytoplasm with large nuclei containing
nucleoli and bi-nucleated (Fig. 4i). Mature HLCs main-
tained in Williams' Media E exhibited homogeneous
population (Fig. 4j), hepatic triad-like structure (Fig. 4k)
and some populations produced bile pigment (Fig. 4l).
HLCs exhibited polygonal morphology during passages
(Fig. 4m). HLCs showed the capability to synthesize
and store glycogen greater than did hMSCs as detected
by Periodic acid Schiff staining (Fig. 4n and o). The
HLCs were also positive for gene expressions of α-
fetoprotein, albumin and HNF4-α using quantitative
RT-PCR (Fig. 4p). For major metabolic functions in
hepatocyte involving carbohydrate, lipid and amino acid
metabolism, HLCs expressed both glucose-6-phosphate
dehydrogenase (G-6-PD) and tyrosine aminotransferase
(TAT). The expression levels of basic hepatocyte
markers (i.e., ALB, AFP, HNF4-α, and TAT) were in-
creased between 10–20 folds over those from undiffer-
entiated iPS cells.
The elevated expression levels of most basal CYP450
isozymes in mature HLCs were inducible with prototypic
inducers
To achieve fully functional hepatocyte, mature HLCs
were maintained in 10 % FBS Williams’ Media E for 3 d
and the cells were screened for CYP expression. HLCs
expressed a number of CYP isozymes as illustrated by
immunostaining and quantitative real-time PCR. The
basal mRNA levels of CYP2B6, CYP2D6, and CYP2C9
in HLCs were 22-, 25-, and 20-fold that of HepaRG cells
respectively; while CYP3A4, CYP2C19, CYP1A2 were
around 10 folds. CYP2E1 in HLCs was up-regulated to
40-fold that of the undifferentiated iPS cells (Fig. 5a).
Other isozymes achieved comparable expression levels
to those of HepaRG and the primary human hepato-
cytes. To evaluate the inducibility of these CYP iso-
zymes, the HLCs were incubated with the cocktail of
chemical inducers (20 μM rifampicin, 50 μM omepra-
zole, 1 mM phenobarbital and 88 μM ethanol). The ex-
pressions of CYP2B6, CYP2C9, CYP2C19 and CYP3A4
in HLCs were increased to 2, 2, 4, 3.5 folds respectively
after the induction with the cocktail. In comparison, the
expressions of CYP2B6, CYP2C9 and CYP3A4 in
HepaRG were increased to 2, 2, 3.5 folds and compar-
able to those in HLCs (Fig. 5b). In particular, some CYP
isozymes, e.g. CYP2B6, CYP2C9, CYP2C19 and CYP2E1
were more inducible in HLCs than in HepaRG cells. The
expression levels of CYPs in primary human hepatocytes
were dramatically decreased post-induction by 72 h. In
addition to CYP expressions, HLCs contained high levels
of organic anion transporting polypeptide 2 (OATP2).
The elevated OATP2 expression could be extensively up
regulated to 3 folds. For protein determination, more
than 50 % of HLC populations were positive for intracel-
lular CYP1A1, CYP3A4, CYP2B6 and CYP2E1 proteins
(Fig. 5c–g). The immunofluorescent straining demon-
strated the increasing expression of major CYP proteins
(Fig. 5c–g), e.g., CYP3A4, CYP2B6, CYP1A1, CYP2C9
and CYP2E1. HLCs expressed multidrug resistance-
associated protein 2 (MRP2) that represented the cana-
licular (apical) membrane of the hepatocyte as a biliary
transport (Fig. 5h). The hMSC served as a control of
non-hepatic cell (Fig. 5i). The increasing of CYP450 ac-
tivities was investigated in hepatocytes (Fig. 5j). Mature
HLCs population could proliferate, but still maintained
hepatic morphology without losing basal levels of hep-
atic related gene expression.
HLCs expressed all major hepatitis C virus cell associated
receptors
A potential application for HLCs is for the study of
pathogen-host cell interactions. The HLCs derived from
iPS cells were evaluated for the capability to host HCV
replication. The expression of HCV receptors is essential
Fig. 3 The pluripotency of human iPS cell derived from hMSCs. The
iPS cells were cultured in complete medium with 20 % FBS or injected
into nude mice to investigate in vitro and in vivo differentiation. The
spontaneous differentiation of iPS cells appeared heterogeneous cell
morphology. After staining with specific antibodies, differentiated cell
positive for βIII-tubulin (ectoderm), α-smooth muscle actin (mesoderm)
and α-fetoprotein (endoderm) (a). In vivo differentiation of iPS
cell, histological examination of teratoma in nude mice after infected
with iPS cells. The teratoma section contained various types of
tissue including neural rosette (ectoderm), mesoderm-derived smooth
muscle, adipose tissue, cartilage (mesoderm) and endoderm-derived
gut-like epithelial (endoderm) (b)
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Fig. 4 (See legend on next page.)
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Fig. 4 The direct differentiation of iPS cell into fully the functional homogenous HLCs. The iPS cells in feeder-free condition at 60 % confluence
(a) were differentiated into definitive endoderm with round-shaped morphology (b). During differentiation induction, cells were positive for
Sox17 (c). During anterior definitive endoderm (ADE) development, the differentiated cells underwent epithelial to mesenchymal transition (EMT)
(d). The ADE cells with oval-shape (e) served as hepatic progenitors. Differentiated cells were positive for α-fetoprotein (f), albumin (g) and
HNF-4α (h). The homogenously mature HLCs exhibited polygonal morphology (i), cord-like structure with bile canaliculi (j) and hepatic
sinusoidal-like structures (k). The HLCs were positive for bile pigment (l). The 2nd passage of HLCs still maintained the hepatic morphology (m).
HLCs and hMSCs were examined for glycogen storage using PAS assay (n, o). HLCs, HepaRG and primary human hepatocyte were compared for the
expressions of hepatocyte selective genes (p). Data were presented as a fold changes over the undifferentiated iPS cells. * and ** represented stat-
istical different data with a p value <0.05 or <0.01 respectively
Fig. 5 The detection of function CYP450 isoenzymes in HLCs. Mature HLCs were investigated for CYP450 expression, protein levels and activities.
HLC, HepaRG and primary hepatocyte were studied for the expression of CYP450 isoenzymes and presented as fold changes over the undifferentiated
iPS cells (a). The CYP450 induction with the cocktail of inducers was evaluated and presented as fold changes over the corresponding untreated cells
(b). * and ** represented statistical different data with a p value <0.05 or <0.01 respectively. The levels of CYP3A4 (c), CYP2B6 (d), CYP1A1 (e), CYP2C9
(f) and CYP2E1 (g) in untreated HLCs and inducer-treated HLCs were measured. Bile canaliculi marker (MRP2) was observed in HLCs (h), but
not in human fibroblasts (i). The CYP450 activities (j) were assayed and presented as a relative light unit (RLU) over the corresponding untreated cells
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for virus hepatitis C viral entry. Mature HLCs expressed
all major receptors for HCV entry (Fig. 6a–c), e.g., spe-
cific tight junctions: claudin-1, occludin; cell surface re-
ceptor: TAPA-1 (CD81); scavenger receptor B1 (SR-BI),
ApoB and ApoE. The expression of specific HCV recep-
tors was increased together with the maturation stage of
HLCs. On the cell surface of cultured HLCs, the protein
products of these receptors were also detected (Fig. 6d–
i), e.g., claudin-1, occludin, SR-BI, CD81, LDL-R and
ApoE. Human fibroblast served as a negative control
(Fig. 6j).
Hepatocyte-like cells support HCVcc virus production
through JFH-1 system
To determine if HLCs could replace the Huh7 cells to
host HCV, HLCs were transfected with JFH-1 RNA
using liposomal transfection [14]. Seven days after trans-
fection, we found cytopathic effect with the aberration
of cytoplasm in HLCs, but not with mock transfection
(Fig. 7a and b). These cells had lower growth rate, aggre-
gated and formed clusters of syncytial cells (Fig 7c).
These findings suggested that HCV might re-infect the
HLCs in high titer. We could not observe the CPE nor
the aberration of cytoplasm in mock transfection or
JFH-1 transfected Huh7 cell on day 7 and day 14
(Fig. 7d–f ). Conditioned medium from HLCs and Huh7
was harvested every 3 d and filtered through a 0.45 μM
syringe filter. The suitable multiplicity of infection
(MOI) was optimized using 10-fold HCV dilution. Cell
viability was determined with MTT assay (Fig. 7g and h).
The HCV viral load was determined and compared be-
tween different cell lines (Fig. 7i). The kinetics of viral
Fig. 6 Identifications of HCV cell-associated receptors and essential host factors on HLCs. Gel electrophoresis from RT-PCR products confirmed the
expression of major HCV cell-associated receptors in iPS cell, Huh7 and HLCs (a, b). The expression levels of HCV cell-associated receptors and
essential host factors (claudin-1, occludin, SR-BI, CD81, ApoE, ApoB, LDL-R, miR-122 and SEC14L2) in HLCs, HepaRG and primary hepatocyte
were determined using real-time RT-PCR (c). * and ** represented statistical different data with a p value <0.05 or <0.01 respectively. Cellular
localization of HCV cell-associated receptors was visualized using immunofluorescent straining. HLCs were visualized for claudin-1 (d), occludin
(e), SR-BI (f), CD81 (g), LDL-R (h) and ApoE (i) in comparison to those observed in human fibroblasts (j)
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production varied depending on the hosting cells. The
maximal HCV production was achieved between 12-15
d post-transfection. HCV viral load from Huh7 was
about 105 IU/mL but HLCs could provide up to 107 IU/
mL (Fig. 7i), comparable to those offered (108 IU/mL) by
the transfected Huh7.5 [17]. The detection of HCV in
HLCs supernatant was maintained beyond 1 month. In
transfected Huh7 cells, HCV viral load was decreased to
104 IU/mL within 2 weeks and completely vanished in
two months (Fig. 7i and j).
Completion of the wild-type HCV life cycle in HLC and the
production of HCV progeny
The naïve HLCs and naïve Huh7 cells were infected with
either HCVcc (JFH-1 genotype 2a) or with HCVser of
various genotypes including 1a, 1b, 3a, 3b, 6f and 6n.
Fig. 7 Production of HCVcc (JFH-1) in HLCs and the viral propagation kinetics. HLCs were either mock transfected (a) or transfected with JFH-1
RNA to produce HCVcc had induced cytopathic effect, cell aberrations (CPE) on day 7 (b) and syncytial formation (c) on day 14. In comparison,
Huh7 cells were either mock transfected (d) or transfected with JFH-1 RNA on day 7 (e) and 14 (f). Cell viability assay using MTT in HLCs (g) and
Huh7 (h) corresponded to the MOI of HCVcc. The kinetics of HCV production in the culture medium were investigated using Abbott real-time HCV
assay (i); while the kinetics of HCV replication were investigated using stand-specific real-time RT-PCR (j) in Huh7, HLCs and HepaRG cells
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HCVcc could be obtained from the earlier transfection
of HLCs or Huh7 with JFH-1 RNA. HCVser was col-
lected from chronic hepatitis C patient. The cytopathic
effect (CPE) in the infected cells was observed on both
day 7 and 14 after infection (Fig. 8a–c). The cytoplasmic
localization of non-structural proteins: NS3A, NS5A,
NS5B and structural protein: HCV core antigen was
clearly detected. Therefore, HLCs allowed both HCV
entry and the transcription of viral RNA (Fig 8d–h). To
ensure that the HLCs support entire HCV life cycle, the
Fig. 8 HLCs supported entire HCVcc and HCVser life cycle. Uninfected HLC (a) or HLCs infected with HCVcc (JFH-1) or HCVser (genotype 1a) were
observed for CPE and cytoplasmic aberrations (b, c). Uninfected HLCs (d), or HLCs after the infection for 14 d were investigated for HCV non-structural
proteins, e.g., zinc-binding phosphoprotein (NS5A) (e), viral RNA polymerase (NS5B) (f), viral protease enzyme (NS3) (g) and the HCV structural protein
(core antigen) (h). The intracellular negative-strand RNA represented the HCV replication (i). The intracellular positive-strand RNA level represented HCV
entry and production (j). HCVser viral load (k) and intracellular RNA (l) in Huh7 and HLCs after natural HCV infection were monitored. The infectivity
titers of HCVcc (m) and HCVser (n) were examine using fluorescent focus forming units (FFU/mL); while the intracellular HCV RNA was determined by
quantitative real-time PCR (RNA log copies/μg of total RNA)
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total RNA prepared from infected HLCs and Huh7 cell
was investigated for the presence of HCV negative-
strand RNA using specific RT-PCR primers. The viral
RNA was maintained in infected cells up to 4 weeks in
HLCs 2 weeks in Huh7 cells. The presence of positive-
strand of viral RNA was measured in the supernatant
from the infected cells using RT-PCR analysis (Fig. 8i
and j). The HCVcc viral loads were 107 IU/mL and
104 IU/mL from the supernatants of HLCs and Huh7,
respectively. The levels of intracellular HCV negative–
strand RNA and positive-strand RNA were determined
by reverse transcription PCR every week after transfec-
tion until 4 weeks. The negative-strand RNA was merely
detectable on day 7 and increased on day 14 (Fig. 8i and
j). For HCVser, HLCs allowed viral propagation as deter-
mined by the increasing HCV particles in culture
medium (Fig. 8k) and the detection intracellular HCV
RNA (Fig. 8l). Huh7 cell, in contrast, could barely hosted
HCV derived from patient serum. The HCVser viral
loads were 104 IU/mL from the supernatants of HLCs.
The kinetics of viral replication post-infection with ei-
ther HCVcc (JFH-1) or HCVser (genotype 1a) in HLCs
were determined using HCV titer and intracellular HCV
RNA. The kinetics of HCV production suggested that
HLCs supported complete HCV replication of both
HCVcc and HCVser (Fig. 8m and n). However, HLCs
did allow HCVser replication beyond 4 weeks (Fig. 8n).
The immunostaining and RT-PCR analysis confirmed
that the entire replication cycle and formation of HCV
progeny took place in HLC and the supernatants from
the infected cultures could efficiently infect naïve HLCs
and Huh7 cells.
The α-tocopherol-pretreated HLCs improved HCV viral
load
The effect of α-tocopherol to HCVser infection was inves-
tigated using HLCs and Huh7 cell line. After the pretreat-
ment with 1 μM or 5 μM α-tocopherol for 24 h and
infection with either HCVcc (JFH-1) or HCVser genotype
1a, the infected HLCs and Huh7 cells were further main-
tained for 14 days. The HCVser viral load was raised to
106 IU/mL in HLCs but the HCVcc viral load was not af-
fected by α-tocopherol. In Huh7 cell, α-tocopherol did not
improve the HCV viral load in HCVser infection and
HCVcc (JFH-1) infection (Fig. 9a and b).
The efficacy study of anti-HCV drugs in infected HLCs
To screen for the sensitivity of infected HLCs to anti-
HCV agents, naïve HLCs were infected with 106 IU/mL
of either HCVcc (from conditioned medium of HLCs) or
HCVser. Different anti-HCV agents or their combina-
tions, e.g., ribavirin (20 μM), IFN-α (10 IU/mL), and
sofosbuvir (PSI-7977, 200 nM) were incubated with the
24-h infected cells for 7 d. The HCV RNA expression in
HCVcc and HCVser served as drug response. The intra-
cellular HCV RNA was determined by real-time qPCR
at 4, 8, 12, and 24 d after the infection initiation. Ribavi-
rin, IFN-α and sofosbuvir were not cytotoxic up to
100 μM, 10 IU/mL and 100 μM respectively. Either riba-
virin or INF-α decreased HCV RNA to 50 % in Huh7
and HLCs. The combination of INF-α and ribavirin de-
creased viral RNA to 20 %. Sofosbuvir decreased viral
RNA below 20 %. (Fig. 9c and d). The IC50 of INF-α
toward HCV RNA level in HLCs and Huh7 cells were
5.3 and 2.4 IU/mL respectively (p < 0.01). The IC50 of
ribavirin in HLCs and Huh7 were 6.9 and 3.2 μg/mL
respectively (p < 0.01). The IC50 of sofosbuvir in HLCs
and Huh7 were 96 and 92 nM respectively (p < 0.01)
(data not shown).
Host inflammatory response and the maintenance of
long-term HCVcc propagation in HLCs
Relative real-time qPCR on days 3 and 14 revealed that
the expression of inflammatory markers, e.g. TNF-α, IL-
28B and IL-29 were inducible during the infection.
Particularly, IL-28B expression in response to HCV in-
fection was observed earlier only in primary human
hepatocyte, but also in our HLCs model (Fig. 9e). Long-
term HCVcc production was evaluated by infecting naïve
HLCs with viral load 107 IU/mL for 72 h. The cell
culture medium that had been replaced every week still
carried HCV particles up to 6 months. The kinetics of
HCV represented the new viral particles releasing from
infected cell to the medium (Fig. 9f ). At 4-week post-
infection, the HCVcc viral load varied from 104 to
105 IU/mL and increased at 2-3 months later to 105 IU/
mL. The HCV viral production was still maintained at
104-105 IU/mL up to 5 months. Until 6 months, most of
the HLCs died in accordance with the viral CPE.
Discussion
Our study demonstrated that HLCs could host HCV for
at least 6 months while retaining the capability to allow
a complete viral life cycle. In these regards, HLCs are su-
perior to the classical HCV host, the Huh7 cells. Despite
HLCs had been studied in association with HCV, only a
brief infection with JFH-1 had been addressed. These
earlier studies employed immature and heterogeneous
HLCs derived from iPS/ES cells as host cells for HCVcc
infection [27, 28, 30]. These cells did not express all of
major functional CYP450s and were functionally imma-
ture that constrained the study of HCV-host interactions
[39–42]. We expanded this observation by elucidating
the mature HLCs not only as a viral target, but as a pro-
ducer of new viral particles to complete a viral life cycle.
We modified the previous hepatic differentiation
protocol [31, 43, 44] to achieve homogenous population
of fully functional HLCs by extending the maturation
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step. The differentiated cells were challenged with a
cocktail of CYP inducers. During hepatic differenti-
ation, the differentiated cells expressed hepatic lineage
markers (Sox17, AFP and albumin). In final step, we
observed the homogeneous of hepatocyte-like cell with
bile canaliculi, hepatic triad-like structure and bile pig-
ments. HLCs were positive for hepatocyte selective
markers, e.g., HNF-4α and tyrosine aminotransferase
(TAT). The expression level of hepatic markers was
higher than those of HepaRG cell, but were comparable
to those of primary hepatocyte.
The xenobiotic biotransformation is a crucial and
specialized function of hepatocyte. Previous studies
could drive the differentiation of human iPS cells to
only immature hepatocytes [45, 46]. Our study demon-
strated that HLCs express phase I (CYP2B6, CYP2D6,
CYP2C9 CYP2C19, CYP1A2 and CYP2E1), phase II
drug-metabolizing enzyme (OATP2) and phase III drug
transporters (MRP2) at levels comparable to those of
primary human hepatocytes, but higher than HepaRG,
the hepatocellular carcinoma cell line frequently used
in pharmaceutical industry. The expression of all major
Fig. 9 The enhancing effect of α-tocopherol and the inhibitory effects of anti-HCV drugs on HCV replication. Huh7 (a) and HLCs (b) were treated
with 0, 1, 5 μM α-tocopherol 24 h prior to infection with HCVser and assayed for HCV viral load. For anti-viral treatment, HLCs were either infected
with HCVcc or HCVser (n = 3) for 24 h prior to the treatment with ribavirin, Interferon-α or sofosbuvir for 7 d. Copies of HCV RNA in lysates were
quantified by real-time PCR (c, d). Infected HLCs were assayed for inflammatory markers (e). For long-term maintenance of HCVcc in HLCs, the
supernatants of the infected HLCs were measured for viral load up to 6 months (f)
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CYP450s was inducible with the standard cocktail of
inducers [33].
Cellular polarity is crucial for maintaining hepatic
phenotype and the susceptibility to HCV [47]. At the end
of hepatic induction, four types of HCV receptors on the
basolateral membrane were detected, i.e., claudin-1, occlu-
din, SR-BI and CD81. HCV particles triggered the increase
in CD81 and claudin-1 endocytosis via clathrin [48].
Clathrin-dependent endocytosis and LDL metabolism in-
volved in the processes of HCV entry [49–51]. ApoB and
ApoE were involved in the production of HCVcc in Huh7
cells [52]. Both apolipoproteins and LDL-receptors on ap-
ical membrane correlated with HCV entry and emission
from host cells [53]. The production of infectious particles
depended on VLDL secretion pathway in hepatocytes
[54]. We observed the increasing expressions of ApoE,
ApoB and LDL receptors after maturation.
Since the discovery of JFH-1 replication in Huh7 cells
[11], subclones of Huh7 (Huh7.5 and Huh7.5.1) had
been developed as a replacement for primary hepato-
cytes. HCV has been classified into seven major geno-
types and numerous of subtypes [55–57]. Nonetheless,
JFH-1 is a single unusual HCV strain of genotype 2a.
Other genotypes could not be maintained in Huh7 cells
due to cell tropism and the restrict host range. The ro-
bust propagation systems of full-length HCV clones of
the TN strain (1a) [58], H77 strain (genotype 1a) [59],
JFH-2 (2a) and s310 strain (3a) [60] were developed but
the construction of other HCV genotypes has not been
success. HepG2, Hep3B and HEK293T cells allowed
HCVcc replication [61–63]. However, these cells require
exogenous host factors (e.g., miR-122, claudin-1 and
ApoE) for complete propagation of HCVcc [63]. Novel
culture models that can host various HCV genotypes are
required. Our study showed that HCV production was
sustained for six months in HLCs that had been either
transfected with full-length JFH-1 RNA or infected with
HCV genotype 1a, 1b, 3a, 3b ,6f and 6n. No requirement
for exogenous expression of cellular host factors was re-
quired for the production of HCVcc. HCVcc and HCVser
produced from HLCs could infect naïve hepatocytes.
The essential HCV host factors, miR-122 and
SEC14L2, facilitated the propagation of HCV in cultured
hepatocyte. SEC14-like protein 2 (SEC14L2) promoted
HCVser infection by upregulating vitamin E-mediated
protection against lipid peroxidation. SEC14L2 together
with α-tocopherol transfer protein and cellular retinol-
binding protein involved in cholesterol biosynthetic
pathway [64]. Both miR-122 and SEC14L2 were highly
expressed in HLCs and primary human hepatocytes, but
not Huh7 cells, correlated with the capability to host
HCVser propagation.
After transfection with HCV RNA or infection with
patient serum, we found the CPE in both transfected
and infected HLCs within 7-d post-transfection. HCV
viral load in culture was 104 IU/mL on day 3 and
108 IU/mL on day 15; while the intracellular HCV RNA
was detectable starting on day 3. Taken together, HLCs
supported complete HCV life cycle from JFH-1 system
and from patient serum.
Host cell immune response play a major role in anti-
viral activity which is naturally occurred in animal
models but defective in current cell culture model of
HCV [65]. HLCs were investigated for cellular immune
responses by infecting with HCVcc for 14 d and inflam-
matory cytokines were detected on day 3 and day 14.
The cellular response to HCV infection was clearly
observed in HLCs. In HLCs, the expressions of inflam-
matory cytokines, e.g., TNF-α, IL-28B and IL-29 were
up-regulated during the infection that mimicked the
natural infection in the primary hepatocytes. IL-28B is
associated with the sensitivity of IFN treatment of chronic
hepatitis C patients [66, 67]. These results are typical of an
ongoing inflammatory response in cells that could serve
as indicators for subsequent antiviral strategies.
Our study implicated that our HLCs could substitute
the primary hepatocytes to serve as a generalized host
for HCV. A complete life cycle of the wild-type HCV
could be driven in our culture system. With this encour-
aging observation, an array of applications of HLCs for
the study of hepatocyte-pathogen interactions would be
the next direction. The list of potential pathogens in-
cluded hepatitis B and dengue viruses that have been
conventionally limited to human biopsies, surgical resec-
tion, organ donation and hepatocellular carcinoma cells
from clinical specimens. The obtained host-pathogen in-
teractions would provide a platform for the screening of
efficacious antiviral regimens in accordance with person-
alized medicine.
Conclusions
Here, we have developed the functional homogenous
HLCs starting from hMSCs through iPS cell repro-
gramming. These HLCs were confirmed for eliciting
major hepatic functions including CYP450 activities.
They exhibited the capability for hosting long-term
HCVser infection in cell culture condition, bypassing
the earlier limitation to the genotype 2a. Together with
the expression of SEC14L2 and the addition of α-
tocopherol, the HCVser infection in HLCs were further
intensified. We demonstrated that the production of
HCV genotype 1a, 1b, 3a, 3b ,6f and 6n were sustained
for at least six months in these HLCs. The HCV-
infection was controlled by the upregulation of TNF-α,
IL-28B and IL-29. Taken together, this novel HCV cul-
ture could serve as a model for HCV biology, host im-
mune response, and antiviral strategy.
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